Subtype

Thyroid Gland Neoplasm

Non-malignant189 active trials10 approved drugs63 evidence items

NCIt: C3414
MeSH: D013964

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (126)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 76–100 of 126 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Thyroid Cancer Management in Contemporary Practice: A Systematic Review and Meta-Analysis of Diagnostic Pathways, Surgical Strategies, Airway Challenges, and Mediastinal Extension.
Ahmed Farouk Ibrahim Koraitim, Mahmoud Mostafa Mohamed, Mohammad Abd Elhameed Alwaseef et al. · Clin Ter · Jan 1, 2026 · PMID 42664150 · candidate dictionary pubmed
Clinicopathological Significance of Ultrasound Risk Features and the Taller-Than-Wide Sign for Tumor Advancement in Differentiated Thyroid Cancer: A Single-Center Analysis.
Michał Miciak, Krzysztof Jurkiewicz, Natalia Kalka et al. · Cancer Manag Res · Jan 1, 2026 · PMID 42707738 · candidate dictionary pubmed
Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review.
Yingqi Xiong, Yaxin Hu, Manya Wang et al. · Cancer Manag Res · Jan 1, 2026 · PMID 42719379 · candidate dictionary pubmed
Racial-Ethnic Differences of Community Vulnerability Impact on Pediatric Thyroid Cancer Diagnosis and Surveillance.
David Fei-Zhang, Meredith Osmulski, Christopher Puchi et al. · OTO Open · Jan 1, 2026 · PMID 42741761 · candidate dictionary pubmed
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
· N Engl J Med · 2023 · PMID 37870969 · validated civic_curation pubmed
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
· N Engl J Med · 2020 · PMID 32846061 · validated civic_curation pubmed

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

· Lancet Diabetes Endocrinol · 2021 · PMID 34118198 · validated civic_curation pubmed

Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.

· Horm Metab Res · 2014 · PMID 24570209 · validated civic_curation pubmed

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

· Clin Endocrinol (Oxf) · 2014 · PMID 24354346 · validated civic_curation pubmed

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

· J Clin Oncol · 2014 · PMID 25024077 · validated civic_curation pubmed

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

· J Clin Invest · 2005 · PMID 15630448 · validated civic_curation pubmed

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18682506 · validated civic_curation pubmed

When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?

· Ann Surg Oncol · 2009 · PMID 19472011 · validated civic_curation pubmed

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted

· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

· J Clin Oncol · 2018 · PMID 29072975 · validated civic_curation pubmed

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

· Cancer · 2016 · PMID 27525386 · validated civic_curation pubmed

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2016 · PMID 27460442 · validated civic_curation pubmed

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

· J Clin Endocrinol Metab · 2005 · PMID 16174717 · validated civic_curation pubmed

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18073307 · validated civic_curation pubmed

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

· Ann Surg Oncol · 2011 · PMID 21594703 · validated civic_curation pubmed

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.

· Oncol Lett · 2014 · PMID 24396464 · validated civic_curation pubmed

The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.

· Thyroid · 2012 · PMID 22650231 · validated civic_curation pubmed

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

· J Clin Endocrinol Metab · 2003 · PMID 12727991 · validated civic_curation pubmed

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

· Endocr Relat Cancer · 2013 · PMID 23766237 · validated civic_curation pubmed